Stock listing
NASDAQ:DRMA Dermata Therapeutics, Inc. Stock
Home listing (NASDAQ) of Dermata Therapeutics, Inc.
Follow Dermata Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:DRMA
$0.510 USD -0.031 (-5.7%)
Close on Nov 20, 2026
- Day range
- $0.500 – $0.547 USDNov 20, 2026
- Volume
- 26,595 sharesNov 20, 2026
- Market cap
- $2.52M USDAt the close on Nov 20, 2026 · price × 4.96M shares outstanding
- 52-week range
- $0.500 – $4.660 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.50M USDMedian day 49,938 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DRMA · Home | $0.510 USD | -0.031 (-5.7%) | 26,595 | $0.532 | $0.547 | $0.500 | $0.540 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DRMA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.510 | -0.031 | -5.7% | $0.532 | $0.547 | $0.500 | 26,595 | |
| $0.540 | -0.030 | -5.3% | $0.570 | $0.597 | $0.533 | 70,728 | |
| $0.570 | -0.028 | -4.7% | $0.610 | $0.680 | $0.570 | 76,545 | |
| $0.599 | -0.023 | -3.7% | $0.603 | $0.640 | $0.566 | 48,756 | |
| $0.621 | -0.040 | -6.0% | $0.650 | $0.660 | $0.571 | 160,612 | |
| $0.661 | -0.054 | -7.6% | $0.709 | $0.709 | $0.661 | 14,441 | |
| $0.715 | +0.000 | +0.1% | $0.740 | $0.740 | $0.650 | 79,870 | |
| $0.715 | -0.055 | -7.2% | $0.750 | $0.778 | $0.714 | 45,068 | |
| $0.770 | +0.006 | +0.8% | $0.782 | $0.813 | $0.719 | 36,719 | |
| $0.764 | +0.002 | +0.3% | $0.757 | $0.836 | $0.734 | 60,212 | |
| $0.762 | -0.093 | -10.9% | $0.850 | $0.850 | $0.762 | 49,938 | |
| $0.855 | +0.006 | +0.7% | $0.844 | $0.870 | $0.803 | 51,881 | |
| $0.849 | +0.095 | +12.6% | $0.757 | $0.909 | $0.720 | 224,952 | |
| $0.754 | -0.021 | -2.7% | $0.771 | $0.819 | $0.744 | 140,372 | |
| $0.775 | -0.066 | -7.9% | $0.799 | $0.829 | $0.764 | 61,673 | |
| $0.841 | -0.034 | -3.8% | $0.880 | $0.880 | $0.823 | 31,522 | |
| $0.875 | +0.120 | +15.9% | $0.770 | $0.890 | $0.750 | 169,729 | |
| $0.755 | +0.037 | +5.2% | $0.736 | $0.770 | $0.673 | 186,890 | |
| $0.718 | -0.063 | -8.1% | $0.765 | $0.780 | $0.703 | 114,084 | |
| $0.781 | -0.083 | -9.6% | $0.833 | $0.850 | $0.772 | 119,400 | |
| $0.864 | +0.064 | +8.0% | $0.780 | $0.870 | $0.780 | 137,700 | |
| $0.800 | -0.070 | -8.0% | $0.850 | $0.890 | $0.782 | 221,200 | |
| $0.870 | +0.010 | +1.2% | $0.855 | $0.928 | $0.830 | 181,000 | |
| $0.860 | 0.000 | 0.0% | $0.848 | $0.970 | $0.760 | 851,500 | |
| $0.860 | -0.050 | -5.5% | $0.909 | $0.950 | $0.810 | 2,517,700 | |
| $0.910 | +0.247 | +37.3% | $0.769 | $1.180 | $0.766 | 170,521,300 | |
| $0.663 | -0.197 | -22.9% | $0.860 | $0.860 | $0.603 | 350,800 | |
| $0.860 | -0.030 | -3.4% | $0.890 | $0.900 | $0.840 | 38,100 | |
| $0.890 | -0.130 | -12.7% | $1.000 | $1.010 | $0.887 | 39,600 | |
| $1.020 | -0.050 | -4.7% | $1.080 | $1.080 | $1.010 | 22,100 | |
| $1.070 | -0.050 | -4.5% | $1.100 | $1.100 | $1.050 | 7,000 | |
| $1.120 | -0.010 | -0.9% | $1.140 | $1.140 | $1.110 | 7,400 | |
| $1.130 | +0.020 | +1.8% | $1.120 | $1.145 | $1.110 | 29,600 | |
| $1.110 | +0.005 | +0.5% | $1.160 | $1.160 | $1.090 | 14,100 | |
| $1.105 | -0.005 | -0.5% | $1.160 | $1.160 | $1.080 | 17,600 | |
| $1.110 | +0.010 | +0.9% | $1.080 | $1.130 | $1.060 | 20,800 | |
| $1.100 | -0.030 | -2.7% | $1.100 | $1.120 | $1.100 | 14,700 | |
| $1.130 | +0.010 | +0.9% | $1.120 | $1.175 | $1.115 | 10,400 | |
| $1.120 | -0.020 | -1.8% | $1.140 | $1.160 | $1.100 | 25,000 | |
| $1.140 | -0.030 | -2.6% | $1.150 | $1.200 | $1.130 | 30,300 | |
| $1.170 | +0.050 | +4.5% | $1.150 | $1.250 | $1.120 | 78,100 | |
| $1.120 | -0.030 | -2.6% | $1.180 | $1.180 | $1.120 | 14,400 | |
| $1.150 | 0.000 | 0.0% | $1.170 | $1.190 | $1.150 | 25,800 | |
| $1.150 | -0.010 | -0.9% | $1.150 | $1.180 | $1.140 | 19,700 | |
| $1.160 | 0.000 | 0.0% | $1.180 | $1.190 | $1.140 | 5,600 | |
| $1.160 | +0.010 | +0.9% | $1.120 | $1.200 | $1.120 | 14,300 | |
| $1.150 | +0.020 | +1.8% | $1.110 | $1.174 | $1.100 | 25,700 | |
| $1.130 | -0.020 | -1.7% | $1.160 | $1.187 | $1.060 | 36,900 | |
| $1.150 | -0.040 | -3.4% | $1.180 | $1.270 | $1.150 | 17,700 | |
| $1.190 | -0.010 | -0.8% | $1.230 | $1.230 | $1.160 | 24,900 | |
| $1.200 | -0.010 | -0.8% | $1.210 | $1.225 | $1.180 | 16,400 | |
| $1.210 | -0.040 | -3.2% | $1.240 | $1.280 | $1.210 | 18,400 | |
| $1.250 | +0.040 | +3.3% | $1.220 | $1.312 | $1.210 | 51,100 | |
| $1.210 | -0.020 | -1.6% | $1.230 | $1.259 | $1.201 | 40,300 | |
| $1.230 | -0.050 | -3.9% | $1.280 | $1.369 | $1.210 | 101,900 | |
| $1.280 | -0.020 | -1.5% | $1.310 | $1.310 | $1.250 | 53,400 | |
| $1.300 | +0.010 | +0.8% | $1.270 | $1.310 | $1.250 | 17,400 | |
| $1.290 | -0.050 | -3.7% | $1.300 | $1.330 | $1.270 | 61,700 | |
| $1.340 | -0.120 | -8.2% | $1.470 | $1.580 | $1.340 | 103,400 | |
| $1.460 | -0.150 | -9.3% | $1.590 | $1.590 | $1.460 | 88,000 | |
| $1.610 | -0.110 | -6.4% | $1.700 | $1.720 | $1.590 | 75,000 | |
| $1.720 | +0.090 | +5.5% | $1.650 | $1.720 | $1.500 | 194,600 | |
| $1.630 | +0.210 | +14.8% | $1.430 | $1.630 | $1.410 | 214,000 | |
| $1.420 | +0.040 | +2.9% | $1.380 | $1.470 | $1.360 | 229,800 | |
| $1.380 | -0.090 | -6.1% | $1.490 | $1.490 | $1.360 | 99,200 |
Splits
3 splits since 2023 · NASDAQ:DRMA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-16 | Consolidation |
- Ticker
- NASDAQ:DRMA
- Asset type
- Stock
- Sector
- Consumer goods
- Industry
- Household & personal care
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Dermata Announces U.S. Trademark Registration for TOME(R)
Latest news
Dermata Announces U.S. Trademark Registration for TOME(R)
Nov 18, 2026
Closed $0.54 (-5.3%) on Nov 18, 2026
Dermata Highlights Additional Results and Photos from Cosmetic Study Evaluating Its Tome Foundational Treatment
Nov 17, 2026
Closed $0.57 (-4.7%) on Nov 17, 2026
Q3 2026 Earnings Release
Nov 10, 2026
Closed $0.715 (+0.1%) on Nov 11, 2026
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Third Quarter 2026
Nov 10, 2026
Closed $0.715 (+0.1%) on Nov 11, 2026
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
Nov 5, 2026
Closed $0.762 (-10.9%) on Nov 5, 2026
Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
Oct 29, 2026
Closed $0.775 (-7.9%) on Oct 30, 2026
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
Oct 15, 2026
Closed $0.91 (+37.3%) on Oct 15, 2026
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
Aug 25, 2026
Closed $1.72 (+5.5%) on Aug 25, 2026
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aug 17, 2026
Closed $1.46 (0.0%) on Aug 17, 2026
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
Aug 11, 2026
Closed $1.38 (+27.8%) on Aug 12, 2026
Dermata Therapeutics, Inc. on 6ix
- Sector
- Consumer goods
- Industry
- Household & personal care
- News releases
- 19 in the last 12 months · 93 in all · newest Nov 18, 2026 · oldest 2021
- Decks
- 1 deck · latest Jul 12, 2021
Where Dermata Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DRMA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:DRMA | BOATS | United States | USD |
Valuation
EV/sales −31.0× against a median of 0.7×: the lowest of 10 Household & personal care companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.30M USD
- P/E
- Loss
- EV/sales
- −31.0×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.7×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.22
Household & personal care: the 10 companies nearest in size, of 134 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dermata Therapeutics, Inc. · NASDAQ:DRMA | US$2.52M | −US$2.30M | n/a | −31.0× | n/a | 0.7× | n/a | 0.0× | 1.22 |
| JHS Svendgaard Laboratories Limited · NSE:JHS | US$7.48M | US$8.49M | n/a | 0.7× | 29.9× | 0.4× | −1.1% | 0.1× | n/a |
| La Savonnerie de Nyons SA · EURONEXT:MLSDN | US$7.28M | US$6.24M | 11.2× | 1.3× | 6.6× | 1.9× | 13.5% | 0.2× | n/a |
| Miraculum S.A. · GPW:MIR | US$6.97M | US$10.23M | n/a | 0.8× | 40.6× | 1.0× | −2.0% | 0.5× | n/a |
| Caring Brands, Inc. · NASDAQ:CABR | US$6.91M | −US$759,746 | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.78 |
| Eng Kah Corp. Bhd. · MYX:ENGKAH | US$5.41M | US$1.72M | n/a | 0.2× | n/a | 0.5× | −28.1% | 0.0× | n/a |
| Sea Mild Biotechnology Co., Ltd. · TPEX:7516 | US$4.16M | US$2.23M | 15.5× | 0.2× | 2.4× | 1.2× | 2.6% | 0.1× | n/a |
| Anagenics Limited · ASX:AN1 | US$3.91M | US$3.55M | 19.2× | 1.0× | 6.6× | 1.4× | 6.0% | 0.0× | n/a |
| CCA Industries, Inc. · OTC:CAWW | US$2.64M | US$2.93M | n/a | 0.6× | n/a | 0.8× | −6.8% | 0.1× | 0.08 |
| Skin Laboratory Public Company Limited · SET:SKIN | US$2.50M | US$827,978 | n/a | 0.2× | n/a | 1.0× | −12.0% | 0.0× | n/a |
| Highlander Enterprise S.A. · NEWCONNECT:HER | US$2.14M | US$2.14M | n/a | 16.0× | 8.7× | 54.7× | −194.8% | 0.0× | n/a |
| Median of the others | US$4.78M | US$2.58M | 15.5× | 0.7× | 7.7× | 1.0× | −2.0% | 0.1× | 0.43 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.17 · 1 analyst
- Revenue, year to Dec 2026
- 100K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Gerry Proehl | Chairman, President, and CEO |
| Kyri Van Hoose | Senior Vice President, Chief Financial Officer |
| Cliff Mastricola | Investor Relations |
| Chris Nardo | Senior Vice President, Chief Development Officer |
| Kyra Peckaitis | Vice President, Marketing |
| Maria Bedoya Toro Munera | Senior Vice President of Regulatory Affairs and Quality Assurance |
Board
| Director | Role |
|---|---|
| Gerry Proehl | Chairman, President, and CEO |
| Andrew Sandler | Director |
| Brittany Bradrick | Director |
| David Hale | Lead Director |
| Kathleen Scott | Director |
| Steve Mento | Director |
| Wendell Wierenga | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · After close | +0.1% |
| Q2 2026 | Aug 11, 2026 · After close | +27.8% |
| Q1 2026 | May 13, 2026 · After close | +3.4% |
| Q4 2025 | Mar 27, 2026 | −16.8% |
| Q3 2025 | Nov 14, 2025 · After close | −7.5% |
| Q2 2025 | Aug 13, 2025 · After close | −9.8% |
| Q1 2025 | May 7, 2025 · After close | −7.1% |
| Q4 2024 | Mar 17, 2025 · After close | +2.6% |
| Q3 2024 | Nov 13, 2024 · After close | −3.3% |
| Q2 2024 | Aug 7, 2024 · After close | +12.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 15, 2024 · After close | |
| Q4 2023 | Mar 21, 2024 · After close | +3.8% |
| Q3 2023 | Nov 9, 2023 · After close | −7.7% |
| Q2 2023 | Aug 10, 2023 · After close | −2.6% |
| Q1 2023 | May 11, 2023 · After close | +35.2% |
| Q4 2022 | Feb 21, 2023 · After close | −4.1% |
| Q3 2022 | Nov 10, 2022 · After close | +10.3% |
| Q2 2022 | Aug 15, 2022 · After close | +3.4% |
| Q1 2022 | May 16, 2022 · After close | −7.3% |
| Q4 2021 | Mar 28, 2022 · Before open | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| IPO Roadshow (July 2021) | IPO roadshow | 31 slides | Jul 12, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with series E and series F warrants Announced: about US$3.4M · US$1.46 a share · Warrants at US$1.46 Insiders: Company insiders, including the CEO, CFO and a member of management, are participating at $1.47 per share and accompanying warrants, with warrant exercise price of $1.47 Use of proceeds: General corporate purposes incl. consumer research, launch of direct-to-consumer product, acquisitions, licensing and working capital | Aug 17, 2026 |
| Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants Closed: US$4.1M raised · US$2.04 a share · Warrants at US$2.04 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Insiders: Company insiders, including the CEO, CFO and certain members of management, participated in the offering Use of proceeds: General corporate purposes, including consumer research, launch of OTC acne kit, acquisitions, licensing and working capital | Dec 29, 2025 |
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$6.2M · US$1.284 a share · Warrants at US$1.284 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. Use of proceeds: General corporate purposes, including research, clinical trials, technology development, licensing, acquisitions and working capital | Mar 28, 2025 |
| Private placement of shares of common stock (or pre-funded warrants) and accompanying warrants Closed: US$2.55M raised · US$1.27 a share · Warrants at US$1.27 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Insiders: Company insiders, including the CEO, CFO and certain board members, participated at the same price as other investors Use of proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, licensing and working capital | Jan 23, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$7.00 a unit on Aug 12, 2021.
- Price
- US$7.00 a unit
- Units offered
- 2,571,428 units
- Offering size
- US$18 million
- Underwriters' option
- Up to 385,714 more units
- Underwriters
- Sole Book Running Manager Maxim Group LLC, Brookline Capital Markets · In the order on the cover
- Units delivered
- On or about Aug 17, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 2, 2021 |
| Filed publicly | Jun 10, 2021 |
| Amended 3 times | Newest Aug 6, 2021 |
| Shares registered with an exchange | Aug 11, 2021 |
| Declared effective by the SEC | Aug 12, 2021 |
| Final prospectus, with the price | Aug 16, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 16, 2021 |
| EFFECT · Notice that a registration is effective | Aug 12, 2021 |
| S-1MEF · Registration of more shares for the same offering | Aug 12, 2021 |
| CERT · Exchange's certificate of listing | Aug 12, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 11, 2021 |
| CORRESP · Letter to the SEC | Aug 10, 2021 |
| CORRESP · Letter to the SEC | Aug 10, 2021 |
| S-1/A · Registration statement, amended | Aug 6, 2021 |
| FWP · Free writing prospectus | Jul 12, 2021 |
| CORRESP · Letter to the SEC | Jul 9, 2021 |
All 22 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jul 9, 2021 |
| UPLOAD · Letter from the SEC | Jul 8, 2021 |
| CORRESP · Letter to the SEC | Jul 2, 2021 |
| S-1/A · Registration statement, amended | Jul 2, 2021 |
| UPLOAD · Letter from the SEC | Jun 17, 2021 |
| CORRESP · Letter to the SEC | Jun 10, 2021 |
| S-1 · Registration statement | Jun 10, 2021 |
| UPLOAD · Letter from the SEC | May 20, 2021 |
| DRSLTR · Letter to the SEC with a draft | May 7, 2021 |
| DRS/A · Draft registration statement, amended | May 7, 2021 |
| UPLOAD · Letter from the SEC | Apr 29, 2021 |
| DRS · Draft registration statement | Apr 2, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 16, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 322 | 1.35K | |||||
| Gross profit | -322 | -1.35K | |||||
| Research and development | 2.93M | 8.20M | 4.07M | 5.65M | 3.46M | 1.61M | 2.62M |
| Selling, general and administrative | 4.84M | 4.31M | 3.97M | 4.02M | 4.40M | 1.56M | 1.85M |
| Operating income | -7.77M | -12.5M | -8.04M | -9.67M | -7.86M | -3.17M | -4.47M |
| Depreciation and amortization | 12.5M | 8.04M | 9.67K | 0 | 322 | 1.35K | |
| EBITDA | -242 | 0 | -9.66M | -7.86M | -3.17M | -4.47M | |
| Interest expense | 63.6K | 45.6K | 197.3K | 250.7K | |||
| Income before tax | -7.56M | -12.3M | -7.79M | -9.61M | -7.90M | -3.24M | -4.72M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 250.7K | |
| Net income | -7.56M | -12.3M | -7.79M | -9.61M | -7.90M | -3.24M | -4.72M |
| Earnings per share, basic | -8.16 | -80.32 | -39.99 | -13.92 | -2.43 | -1.69 | -1,360.62 |
| Earnings per share, diluted | -8.16 | -80.32 | -39.99 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.52M | 3.16M | 7.44M | 6.24M | 10.8M | 530.4K | 1.99M |
| Short-term investments | 3.16B | ||||||
| Receivables | 8.36K | 12.6K | |||||
| Current assets | 7.86M | 3.53M | 7.98M | 6.94M | 11.6M | 605.5K | 2.07M |
| Property, plant and equipment | 0 | 0 | 322 | ||||
| Total assets | 7.86M | 3.53M | 7.98M | 6.94M | 11.6M | 605.5K | 2.07M |
| Accounts payable | 460.8K | 808.0K | 866.0K | 496.7K | 515.2K | 104.3K | 337.2K |
| Current liabilities | 1.64M | 1.97M | 1.62M | 922.6K | 1.52M | 3.78M | 1.72M |
| Long-term debt | 553.2K | ||||||
| Total debt | 0 | 556.2K | 1.28M | ||||
| Total liabilities | 1.64M | 1.97M | 1.62M | 922.6K | 1.52M | 3.78M | 2.28M |
| Shareholders' equity | 6.22M | 1.56M | 6.36M | 6.02M | 10.1M | -3.18M | -210.2K |
| Shares outstanding | 2.66M | 251.7K | 262.0K | 770.1K | 8.33M | 12.3M | 3.47K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -7.80M | -11.2M | -6.41M | -8.83M | -5.69M | -4.03M | -3.92M |
| Capital spending | 0 | 0 | 0 | -4 | 0 | 0 | 0 |
| Free cash flow | -7.76M | -11.2M | -6.41M | -8.83M | -5.69M | -4.03M | -3.92M |
| Cash from financing | 12.1M | 6.89M | 7.61M | 4.28M | 16.0M | 2.57M | 4.73M |
| Dividends paid | -2.29M | ||||||
| Share buybacks | -367 | -828 | -40 | -40 | -1.00M | 0 | |
| Change in cash | 4.36M | -4.28M | 1.20M | -4.56M | 10.3M | -1.46M | 812.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2026 | Current report | SEC |
| 424B3 · Prospectus | Oct 21, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 21, 2026 | Other filings | SEC |
| S-3 · Registration statement | Oct 9, 2026 | Offer document | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 25-NSE | Aug 17, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 17, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 8-K · Current report | Aug 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 4, 2026 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 1, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jun 1, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 29, 2026 | Offer document | SEC |
| 8-K · Current report | May 27, 2026 | Management or board change | SEC |
| CORRESP · Letter to the SEC | May 27, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | May 22, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 22, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 6, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 25, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 23, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 9, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 2, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Jan 30, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jan 29, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 27, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2026 | Other filings | SEC |
| 8-K · Current report | Jan 27, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 27, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jan 22, 2026 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 8, 2026 | Big-stake notice | SEC |
| D | Jan 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 30, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 29, 2025 | Material contract | SEC |
| S-3 · Registration statement | Nov 21, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 17, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2025 | Results | SEC |
| 8-K · Current report | Nov 7, 2025 | Current report | SEC |
| 424B5 · Prospectus | Nov 7, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 17, 2025 | Current report | SEC |
| 8-K · Current report | Sep 10, 2025 | Current report | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 8-K · Current report | Jul 30, 2025 | Current report | SEC |
| 8-K · Current report | Jul 15, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jul 7, 2025 | Current report | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Jun 2, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 2, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 2, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | May 21, 2025 | Current report | SEC |
| 8-K · Current report | May 16, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 9, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 24, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 23, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 21, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 21, 2025 | Other filings | SEC |
| S-3 · Registration statement | Apr 15, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 3, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Mar 28, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| 10-K · Annual report | Mar 17, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 6, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| D/A | Feb 4, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 3, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 3, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jan 30, 2025 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 28, 2025 | Big-stake notice | SEC |
| D | Jan 28, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 23, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 21, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| D | Sep 27, 2024 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Sep 25, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Sep 24, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 23, 2024 | Other filings | SEC |
| S-3 · Registration statement | Sep 19, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 17, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 7, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 2, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jul 15, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jul 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jul 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 8, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jul 3, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 7, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 7, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 5, 2024 | Current report | SEC |
| 8-K · Current report | May 24, 2024 | Current report | SEC |
| 8-K · Current report | May 17, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 8-K · Current report | May 15, 2024 | Current report | SEC |
| 8-K · Current report | May 14, 2024 | Current report | SEC |
| 8-K · Current report | May 7, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Mar 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 26, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 21, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 21, 2024 | Results | SEC |
| PRE 14A · Preliminary proxy statement | Mar 1, 2024 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 18, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Dec 15, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Dec 13, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 13, 2023 | Other filings | SEC |
| DEF 14A · Proxy statement | Dec 8, 2023 | Meeting notice | SEC |
| S-3 · Registration statement | Dec 7, 2023 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Nov 29, 2023 | Meeting notice | SEC |
| 8-K · Current report | Nov 17, 2023 | Material contract | SEC |
| 8-K · Current report | Nov 15, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| S-8 · Registration statement for employee plans | Sep 14, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 10, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 3, 2023 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Jul 28, 2023 | Other filings | SEC |
| 424B4 · Prospectus | Jul 27, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 25, 2023 | Other filings | SEC |
This page holds 200 of 374 filings. Open Filings
Cap table
Built by 6ix from Dermata Therapeutics, Inc.’s releases · as of Aug 17, 2026
- Common shares
- 4,955,207
- Fully diluted
- 4,955,207
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 4,955,207 |
Warrants and options
| Lot |
|---|
| Warrants · US$2.04 · expiry not stated |
| Warrants · US$1.27 · expire about Jan 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 4,955,207 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Hale Other companies: Oncternal Therapeutics Inc (Director · Jun 7, 2019 – Jun 20, 2024 · Past); Histogen Inc (Director · Jul 24, 2013 – Jun 27, 2019 · Past); Somaxon Pharmaceuticals Inc (Director · Apr 2, 2012 – Dec 31, 2012 · Past); Santarus Inc (Director · Mar 21, 2012 – Jan 2, 2014 · Past) | Lead Director · Since at least Aug 12, 2021 |
| Andrew Sandler M.D. Other companies: Alpine Immune Sciences Inc (Chief Medical Officer · Aug 17, 2022 – Jan 5, 2023 · Past); Dendreon Corp (EVP, Chief Medical Officer · Jan 13, 2014 – Feb 13, 2015 · Past) | Director · Since at least Aug 12, 2021 |
| Wendell Wierenga Other companies: Crinetics Pharmaceuticals, Inc. (Director · Since at least Jun 18, 2026); Cytokinetics, Incorporated (Director · Since at least Oct 15, 2025) | Director · Since at least Aug 12, 2021 |
| Brittany Bradrick Other companies: Spectrum Pharmaceuticals Inc (Director · May 4, 2022 – Jul 31, 2023 · Past) | Director · Since at least Jan 12, 2022 |
| Maria E Bedoya-Toro Other companies: Santarus Inc (SVP, Regulatory Affairs & QA · May 28, 2007 – Jan 2, 2014 · Past) | SVP, Regulatory Affairs · Since at least Aug 12, 2021 |
| Chris Nardo | Senior Vice President, Chief Development Officer · Since at least Jun 10, 2025 |
| Christopher J Nardo | Senior VP, CDO · Since at least Aug 12, 2021 |
| Cliff Mastricola | Investor Relations · Since at least Oct 29, 2026 |
| Gerald T Proehl | PRESIDENT, CHAIRMAN, CEO, Director · Since at least Aug 16, 2026 |
| Gerry Proehl | Chairman, President, and CEO · Since at least Aug 18, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Kathleen Scott | Director · Since at least Jun 10, 2025 |
| Kyra Peckaitis | Vice President, Marketing · Since at least Mar 10, 2026 |
| Kyri Van Hoose | Senior Vice President, Chief Financial Officer · Since at least Jun 10, 2025 |
| Maria Bedoya Toro Munera | Senior Vice President of Regulatory Affairs and Quality Assurance · Since at least Jun 10, 2025 |
| Mary Fisher | Director · Since at least Jan 2, 2026 |
| Steve Mento | Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Dermata Therapeutics, Inc.